ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2020
Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Pooled it
- Lymphocyte count is a universal predictor of health outcomes in COVID-19 patients before mass vaccination: A meta-analytical study.Journal of global health · 2022Pooled it
- Elevated Natriuretic Peptides in Patients With Severe or Critical COVID-19: A Meta-Analysis.Texas Heart Institute journal · 2022Pooled it
- Promising traditional Indian medicinal plants for the management of novel Coronavirus disease: A systematic review.Phytotherapy research : PTR · 2021Pooled it
- COVID-19 PICU guidelines: for high- and limited-resource settings.Pediatric research · 2020Guideline
- SARS-CoV-2: A synergy to the Alzheimer's disease.Journal of neurovirology · 2025Review
- Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Critically Ill Pediatric Patient and SARS-CoV-2 Infection.Children (Basel, Switzerland) · 2022Review
- "Anosmia" the mysterious collateral damage of COVID-19.Journal of neurovirology · 2022Review
- Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- PATIENT CLINICAL CONDITION IN RELATION TO HYPOXEMIA AND CHEST X-RAY CHANGES IN NOVEL CoV-19 PNEUMONIA: A CASE REPORT.Acta clinica Croatica · 2021Article
- Review on oxidative stress relation on COVID-19: Biomolecular and bioanalytical approach.International journal of biological macromolecules · 2021Review
- The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.Topics in current chemistry (Cham) · 2021Review
- Possible Male Reproduction Complications after Coronavirus Pandemic.Cell journal · 2021Review
- The identification of novel inhibitors of human angiotensin-converting enzyme 2 and main protease of Sars-Cov-2: A combination ofJournal of molecular structure · 2021Article
- Save the kidneys in COVID-19.Pediatric research · 2021Article
- Immunotherapies and immunomodulatory approaches in clinical trials - a mini review.Human vaccines & immunotherapeutics · 2021Review
- Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports.Cardiovascular drugs and therapy · 2021Review
- Personalized Approach to Patient with MRI Brain Changes after SARS-CoV-2 Infection.Journal of personalized medicine · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since December 2019, the infection of the new coronavirus (COVID-19) caused an outbreak of new coronavirus pneumonia in Wuhan, China, and caused great public concern. Both COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through ACE2. An in-depth understanding of ACE2 and a series of physiological and physiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical phenomena and then deal with them timely. In addition, ACE2 is a potential therapeutic target. This article will summarize the role of ACE2 in multiple organ damage caused by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit inflammation in order to provide the basis for subsequent related research, diagnosis and treatment, and drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.